Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBIT Margin (2016 - 2025)

CorMedix has reported EBIT Margin over the past 12 years, most recently at 46.27% for Q4 2025.

  • Quarterly results put EBIT Margin at 46.27% for Q4 2025, down 14635.0% from a year ago — trailing twelve months through Dec 2025 was 10.11% (up 1943.0% YoY), and the annual figure for FY2025 was 10.11%, up 1944.0%.
  • EBIT Margin reached 46.27% in Q4 2025 per CRMD's latest filing, down from 49.24% in the prior quarter.
  • Across five years, EBIT Margin topped out at 100.08% in Q4 2024 and bottomed at 102126.07% in Q3 2022.
  • Median EBIT Margin over the past 4 years was 8169.54% (2021), compared with a mean of 25281.78%.
  • Peak annual rise in EBIT Margin hit 3304022bps in 2022, while the deepest fall reached -8392529bps in 2022.
  • Over 4 years, EBIT Margin stood at 13794.92% in 2021, then plummeted by -105bps to 28244.66% in 2022, then skyrocketed by 100bps to 100.08% in 2024, then tumbled by -146bps to 46.27% in 2025.
  • Business Quant data shows EBIT Margin for CRMD at 46.27% in Q4 2025, 49.24% in Q3 2025, and 49.18% in Q2 2025.